Last reviewed 2026-04-20 · How we verify

PPV23

Jena University Hospital · FDA-approved active Small molecule Quality 4/100

At a glance

Generic name	PPV23
Also known as	Pneumovax (MSD), 23 valent pneumococcal polysaccharide vaccine, Pneumovax, pneumovax
Sponsor	Jena University Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1,PHASE2)
Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma (PHASE4)
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (EARLY_PHASE1)
A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) (PHASE1)
A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) (PHASE2,PHASE3)
Clinical Trial of Recombinant Pneumococcal Protein Vaccine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results